To farmers and gardeners, the petty spurge is just a weed that needs to be removed from the fields.
But to the pharmaceutical industry, the plant has long been in the spotlight because of its so-called Ingenol substances, which have shown promising results in the fight against cancer.
The problem is that the petty spurge only contains tiny amounts of these special substances, and extracting and refining them from the plant is a costly and ineffective process.
However, scientists have now managed to produce Ingenol synthetically in the laboratory.
“Ingenol has a highly complex structure, and that makes it very hard to produce it chemically. Most organic chemists would probably not have expected that it would be possible to do it as effectively as we have done in our study,” says lead author Lars Jørgensen, a Danish chemist at The Scripps Research Institute in America.
So what is it that makes Ingenol so interesting? According to Jørgensen, derivatives of Ingenol have shown potential in the treatment of the precancerous skin condition actinic keratosis.
Ingenol metubate, a derivative of Ingenol, already exists on the market and is FDA approved for the topical treatment of actinic keratosis.
This gel is manufactured by the Danish pharmaceutical company LEO Pharma, which extracts its Ingenol substances from the petty spurge plant.
”The substance that goes into this gel is extracted from plants, and this process is not only troublesome, it’s also expensive,” says the researcher.
”The plant does not contain much of the substance – for each kilo of the plant, you only get 1.1 milligram of Ingenol Mebutate. That’s why there has been so much focus on producing the substance synthetically in a lab, so that we’ll no longer be dependent on cultivation, harvest and so on.”
However, synthesizing a substance like Ingenol in the laboratory is far from a simple task.
The Ingenol molecule is composed of the elements carbon, oxygen and hydrogen, but these three substances make up a very complex structure. This means that it is not enough simply to mix these substances in a flask and then create Ingenol from it.
”In terms of energy, these substances would assemble into a different structure from that of Ingenol. We therefore needed to take a detour, which forced the molecules to assemble in just the right way.”
This detour consisted of blending various chemicals with the ‘right’ chemicals to make them react with each other. The scientists ended up with a wide variety of substances in their flasks, but eventually they managed to blend and purify the chemicals in just the right way, resulting in the end product Ingenol.
”The strategy we used to solve this challenge was to look at how nature produces Ingenol – i.e. how the enzymes in the petty spurge produce the substance in the plant,” says Jørgensen.
When the petty spurge produces the Ingenol molecule, the plant’s enzymes first construct a skeleton of carbon and hydrogen. In the study, the researchers tried to mimic this process. They then added oxygen to the just right locations on the carbon framework to complete the synthesis, resulting in a molecule which had the right Ingenol architecture.
”We are actually not the first scientists to have synthesized Ingenol in the lab. But what makes our study special is that our method is far more effective, and now suddenly we’re seeing a potential for manufacturing Ingenol on a larger scale,” he says.
Other scientists have previously managed to produce Ingenol through a 37-step synthesis. In other words, they had to make a variety of substances react with each other 37 times before they ended up with the substance Ingenol.
Ingenol is a substance found in the sap of the plant Euphorbia peplus.
A derivative of Ingenol, Ingenol Mebutate, is currently being used to treat the precancerous skin condition actinic keratosis.
Ingenol Mebutate is used in a gel, marketed as Picato by Danish pharmaceutical company LEO Pharma, which currently extracts and refines its Ingenol Mebutate from the petty spurge plant. But the new study may pave the way for the substance to be manufactured synthetically at the company’s laboratories.
Source: Lars Jørgensen, Science
The new study only used 14 steps.
”Our process is more than twice as quick as previous processes, and there are probably a few researchers out there who have doubted whether it was even possible to produce Ingenol in this way. So this is a bit of a prestige project for a chemist,” says Jørgensen.
He explains that the next part of the project will consist of further developing the manufacture of Ingenol and to create new, similar substances that may be used in cancer treatment.
”By modifying the substance we may be able to produce a substance which binds more effectively to cancer cells or which may work in some other way. That’s what we’ll be looking into now.”